Chongkundang (001630) - Total Assets
Based on the latest financial reports, Chongkundang (001630) holds total assets worth ₩1.60 Trillion KRW (≈ $1.08 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Chongkundang for net asset value and shareholders' equity analysis.
Chongkundang - Total Assets Trend (2000–2024)
This chart illustrates how Chongkundang's total assets have evolved over time, based on quarterly financial data.
Chongkundang - Asset Composition Analysis
Current Asset Composition (December 2024)
Chongkundang's total assets of ₩1.60 Trillion consist of 29.3% current assets and 70.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.0% |
| Accounts Receivable | ₩123.90 Billion | 8.3% |
| Inventory | ₩237.71 Billion | 15.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩22.80 Billion | 1.5% |
| Goodwill | ₩8.62 Billion | 0.6% |
Asset Composition Trend (2000–2024)
This chart illustrates how Chongkundang's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Chongkundang market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chongkundang's current assets represent 29.3% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, up from 1.2% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 15.9% of total assets.
Chongkundang Competitors by Total Assets
Key competitors of Chongkundang based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
China | CN¥3.34 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF21.61 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.22 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Chongkundang - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.78 | 0.89 | 1.41 |
| Quick Ratio | 0.39 | 0.44 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-139.87 Billion | ₩-53.20 Billion | ₩114.00 Billion |
Chongkundang - Advanced Valuation Insights
This section examines the relationship between Chongkundang's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.37 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | ₩1.50 Trillion |
| Market Capitalization | $160.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chongkundang's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Chongkundang's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Chongkundang (2000–2024)
The table below shows the annual total assets of Chongkundang from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.50 Trillion ≈ $1.01 Billion |
+2.73% |
| 2023-12-31 | ₩1.46 Trillion ≈ $986.71 Million |
+5.79% |
| 2022-12-31 | ₩1.38 Trillion ≈ $932.75 Million |
+0.64% |
| 2021-12-31 | ₩1.37 Trillion ≈ $926.83 Million |
+8.68% |
| 2020-12-31 | ₩1.26 Trillion ≈ $852.83 Million |
+17.09% |
| 2019-12-31 | ₩1.07 Trillion ≈ $728.34 Million |
+23.33% |
| 2018-12-31 | ₩871.44 Billion ≈ $590.56 Million |
+6.42% |
| 2017-12-31 | ₩818.86 Billion ≈ $554.93 Million |
+16.04% |
| 2016-12-31 | ₩705.67 Billion ≈ $478.22 Million |
+40.85% |
| 2015-12-31 | ₩501.01 Billion ≈ $339.52 Million |
+65.54% |
| 2014-12-31 | ₩302.66 Billion ≈ $205.11 Million |
+9.06% |
| 2013-12-31 | ₩277.52 Billion ≈ $188.07 Million |
-60.80% |
| 2012-12-31 | ₩708.02 Billion ≈ $479.81 Million |
+4.82% |
| 2011-12-31 | ₩675.48 Billion ≈ $457.77 Million |
+21.96% |
| 2010-12-31 | ₩553.85 Billion ≈ $375.33 Million |
+20.35% |
| 2009-12-31 | ₩460.21 Billion ≈ $311.88 Million |
+2.14% |
| 2008-12-31 | ₩450.57 Billion ≈ $305.34 Million |
+9.36% |
| 2007-12-31 | ₩412.01 Billion ≈ $279.22 Million |
+3.90% |
| 2006-12-31 | ₩396.56 Billion ≈ $268.75 Million |
+11.09% |
| 2005-12-31 | ₩356.98 Billion ≈ $241.92 Million |
+7.51% |
| 2004-12-31 | ₩332.05 Billion ≈ $225.02 Million |
-15.59% |
| 2003-12-31 | ₩393.38 Billion ≈ $266.59 Million |
-6.48% |
| 2002-12-31 | ₩420.64 Billion ≈ $285.06 Million |
-13.69% |
| 2001-12-31 | ₩487.37 Billion ≈ $330.29 Million |
-16.21% |
| 2000-12-31 | ₩581.68 Billion ≈ $394.20 Million |
-- |
About Chongkundang
Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. Chong Kun Dang Holdings Corp. was founded in 1941 and is based in Seoul, South Korea.